However, despite the extended cytarabine inclusion in ALL chemotherapy regimens, the outcomes for KMT2A-r-ALL remain poor; this has prompted the development of new molecules targeting the KMT2A pathway such as menin inhibitors. Here, KMT2A is linked to acute lymphoblastic leukemia.